scholarly journals Efficacy and safety analysis on dendritic cell-based vaccine-treated high-grade glioma patients: a systematic review and meta-analysis

2018 ◽  
Vol Volume 11 ◽  
pp. 7277-7293 ◽  
Author(s):  
Changling Li ◽  
Ting Liu ◽  
Bo Zhou ◽  
Yubin Zhou ◽  
Huiying Yu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Dendritic Cell ◽  
Meta Analysis ◽  
High Grade Glioma ◽  
Safety Analysis ◽  
High Grade ◽  
Efficacy And Safety ◽  
Dendritic Cell Based Vaccine

scholarly journals Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis

Oncotarget ◽  
2017 ◽  
Vol 8 (31) ◽  
pp. 51758-51765 ◽  
Author(s):  
Weilin Xu ◽  
Tao Li ◽  
Liansheng Gao ◽  
Jingwei Zheng ◽  
Anwen Shao ◽  
...  
Keyword(s):  
Meta Analysis ◽  
High Grade Glioma ◽  
Term Therapy ◽  
High Grade ◽  
Efficacy And Safety ◽  
Long Term Therapy

scholarly journals Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Ning Ren ◽  
Leyin Zhang ◽  
Jieru Yu ◽  
Siqi Guan ◽  
Xinyang Dai ◽  
...  
Keyword(s):  
Systematic Review ◽  
Ovarian Cancer ◽  
Combination Therapy ◽  
Data Extraction ◽  
Meta Analysis ◽  
Parp Inhibitor ◽  
Recurrent Ovarian Cancer ◽  
Parp Inhibitors ◽  
High Grade ◽  
Efficacy And Safety

ObjectivesThough it is known to all that PARP inhibitors (PARPis) are effective when used as maintenance alone for women with recurrent ovarian cancer (ROC), little is known about whether using them in combination with other drugs would contribute to a better efficacy. We performed a systematic review and meta-analysis to explore the efficacy and safety of PARPi combination therapy compared with monotherapy.Materials and MethodsWe searched for randomized controlled trials (RCTs) that offered the date we needed in PubMed, Embase, Cochrane, and major conference. Data extraction and processing were completed by three investigators to compare OS, PFS, and ORR both in intervention and in control subset. Then, we calculated the pooled RR and 95% CI of all-grade and high-grade adverse effects to study its safety. And we evaluated the within-study heterogeneity by using subgroup and sensitivity analysis.Results and ConclusionA total of three eligible RCTs covering 343 women were included. In PFS analysis, PARP inhibitor (PARPi) combination therapy can significantly improve PFS for women with ROC when compared with the controls (HR: 0.46, 95% CI: 0.35 to 0.59), especially for those with mutated BRCA (HR: 0.29, 95% CI: 0.19 to 0.45). And in OS analysis, combination therapy is not inferior to monotherapy (HR: 0.90, 95% CI: 0.50 to 1.61). As for ORR, the effectiveness of combination therapy and monotherapy was almost the same (RR: 1.04, 95% CI: 0.82 to 1.31). Additionally, combination therapy seldom causes more adverse events, both in all-grade and in high grade.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, International Prospective Register of Systematic Reviews (PROSPERO) (identifier, CRD42018109933).

scholarly journals PDCT-17. SURVIVAL OUTCOMES IN PEDIATRIC RECURRENT HIGH-GRADE GLIOMA: RESULTS OF A 20-YEAR SYSTEMATIC REVIEW AND META-ANALYSIS

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi187-vi187
Author(s):  
Cassie Kline-Nunnally ◽  
Erin Felton ◽  
Elaine Allen ◽  
Peggy Tahir ◽  
Sabine Mueller
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
High Grade Glioma ◽  
Survival Outcomes ◽  
High Grade
Sign in / Sign up

Export Citation Format

Share Document